← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Beckman Research Institute Of The City Of Hope
$41,980,771
Total funding
49
Grants
Funding over time
peak $11.7M · FY2008–25$20M$15M$10M$5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$41,192,537 · 46
USDA$788,234 · 3
By mechanism
—$41,980,771 · 49
Investigators at Beckman Research Institute Of The City Of Hope
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
DIGITAL HEALTH INTERVENTION FOR SELF-MANAGEMENT AND TELEMONITORING IN CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY$5,339,958
· FY2025 · Defense Health Agency
INTEGRATED IMMUNOTHERAPY FOR BREAST CANCER$3,143,805
· FY2012 · Department of the Army
ENHANCING THE BREADTH AND EFFICACY OF THERAPEUTIC VACCINES FOR BREAST CANCER$2,472,750
· FY2011 · Department of the Army
DEVELOPMENTAL THERAPEUTICS AND POTENTIAL TREATMENT TARGETING RALBP1 FOR CASTRATION-RESISTANT PROSTATECARCINOMA$2,136,000
· FY2025 · Defense Health Agency
REPURPOSING ANTIPARASITIC DRUG IVERMECTIN FOR COMBINATION IMMUNOTHERAPY TO COMBAT METASTATIC BREAST CANCER$1,759,998
· FY2022 · Department of the Army
POTENTIATING T CELL ACTIVITY AGAINST MULTIPLE MYELOMA THROUGH SUMOYLATION INHIBITION$1,759,998
· FY2025 · Defense Health Agency
GENOMIC BIOMARKER DRIVEN TREATMENT STRATEGY FOR PERIPHERAL T-CELL LYMPHOMA$1,361,902
· FY2022 · Defense Health Agency
DUAL-FUNCTION CPG-STAT3 ANTISENSE OLIGONUCLEOTIDES FOR$1,320,000
· FY2019 · Department of the Army
TARGETING DIABETES-ASSOCIATED RADIORESISTANCE TO IMPROVE PROSTATE CANCER CONTROL AND QUALITY-OF-LIFE OUTCOMES$1,319,487
· FY2025 · Defense Health Agency
RLIP76: A NOVEL STRATEGY FOR PREVENTING AND TREATING BREAST CANCER$1,275,000
· FY2016 · Department of the Army
IMPACTING QUALITY OF LIFE AND PANCREATIC CANCER SURVIVORSHIP THROUGH A TELEHEALTH INTERVENTION$1,175,982
· FY2024 · Defense Health Agency
MERCAPTURIC ACID PATHWAY INHIBITORS AS A NOVEL TREATMENT FOR OVARIAN CANCER$1,056,000
· FY2022 · Department of the Army
MOLECULAR TARGET FOR NEUROBLASTOMA THERAPY$1,008,500
· FY2011 · Department of Defense
PERIOPERATIVE OSTOMY SELF-MANAGEMENT TELEHEALTH INTERVENTION FOR CANCER SURVIVORS$999,997
· FY2024 · Defense Health Agency
BREAST CANCER SELECTIVE THERAPEUTIC DEVELOPMENT: LEAD OPTIMIZATION OF A SMALL-MOLECULE INHIBITOR OF THE BREAST CANCER SELECTIVE HUB PROTEIN CAPCNA$973,480
· FY2019 · Defense Health Agency
LOCAL GM-CSFR BLOCKADE TO IMPROVE OUTCOME IN LEPTOMENINGEAL DISEASE FROM BREAST CANCER$954,204
· FY2019 · Defense Health Agency
USING LUMINAL EPITHELIAL CELLS LIKE CANARIES IN A COAL MINE: AGING BIOMARKERS FOR TRACKING BIOACTIVITY OF CHEMOPREVENTION AND FOR ESTIMATES OF CANCER RISK$879,101
· FY2019 · Department of the Army
A ROLE OF PEPTIDYLARGININE DEIMINASES IN MEDIATING IMMUNE EVASION OF TRIPLE-NEGATIVE BREAST CANCER$800,643
· FY2025 · Defense Health Agency
IMMUNOTHERAPEUTIC TREATMENT FOR EBV-ASSOCIATED LYMPHOMAS$704,000
· FY2020 · Department of the Army
NOVEL CAR-T THERAPY TARGETING BAFF-R AGAINST B-CELL LYMPHOMAS$692,000
· FY2018 · Department of the Army